Cushing’s syndrome, or hyperadrenocorticism (HAC), is one of the most common endocrine diseases in dogs, affecting approximately 1-2 dogs per 1,000 (Schofield et al., 2022). It is often difficult to diagnose due to non-specific clinical signs and the lack of a single, highly accurate test. As a result the prevalence of the disease is expected to be much higher than reported.
Offering the flexibility to be precise, each Trilotab tablet is divisible into halves and quarters to facilitate dose adjustment when tailoring the dose to each individual pet. It also enables easy administration and simplified, cost-effective dosing protocols for pet owners. Tablets are stable outside of the blister packaging until the next administration to avoid unnecessary wastage.
Trilotab tablets are chewable and chicken flavoured to help improve treatment compliance and specifically utilise hydrolysed chicken flavouring to facilitate prescription in pets allergic to chicken.
Available in 10mg, 30mg, and 60mg presentations, Trilotab also supports veterinary practices to reduce their dispensary stockholding by allowing precise dosing with just 3 presentations.
Eighty-five percent of spontaneous cases of Cushing’s are pituitary- dependant hypercortisolism (PDH) caused by an adrenocorticotrophic hormone (ACTH)-secreting pituitary adenoma; the remaining 15 percent of spontaneous cases are adreno-dependent hyperadrenocorticism (ADH) caused by a cortisol-secreting adrenocortical tumour (ACT) (Sanders et al., 2018). Trilotab is licensed to treat both PDH and ADH.
Trilostane selectively and reversibly inhibits the enzyme system 3 beta hydroxysteroid isomerase, blocking the production of cortisol, corticosterone and aldosterone. Clinical improvement is usually seen within 2 weeks of starting treatment and in those dogs that respond to trilostane, adequate control is achieved within 30 days (Church, 2018).
“The complex nature of Cushing’s syndrome in dogs can make it a challenging condition to manage for both the clinician and the pet owner”, said Andrew Connolly, marketing director for UK and Ireland at Virbac. “With the requirement for lifelong treatment, it is our hope that Trilotab’s easy administration and simplified dosing protocols will genuinely help to improve the lives of dogs affected by the disease, whilst making the clinician and pet owner’s lives just a little bit easier too!”
Trilotab is administered once daily with food with a starting dose of 2mg trilostane/kg bodyweight. The individual response to treatment should be monitored and combinations of the easily divided tablets can be used to adjust the dose to the lowest necessary to control the clinical signs of the disease.
Virbac are offering a wide range of support materials to make switching to Trilotab simple for both your practice and your clients.
For more information on Trilotab, and the support available to you and your practice, please speak to your Virbac Territory Manager.
